You are here:HomePharma

Pharma

  • Dr Reddy's Acquires Habitrol Brand

    Dr Reddy's Acquires Habitrol Brand

    City-based drug maker Dr Reddy's Laboratories has acquired Habitrol brand, a nicotine replacement therapy transdermal patch, from Novartis Consumer Health Inc.

  • Novartis Sues Cipla Over Respiratory Drug

    Novartis Sues Cipla Over Respiratory Drug

    Swiss drug maker Novartis AG said on Wednesday it had sued Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

  • Price Performance of Pharma StocksOther Stories
  • Emami Partners With Germany's Hevert-Arzneimittel

    Emami Partners With Germany's Hevert-Arzneimittel

    Home grown FMCG firm Emami has enetered into a partnership with German homoeopathic firm Hevert-Arzneimittel for manufacturing and marketing of select Hevert formulations in India.

  • Strides Arcolab Gets USFDA Nod for Calcitriol Softgel Capsules

    Strides Arcolab Gets USFDA Nod for Calcitriol Softgel Capsules

    The company has received approval from the United States Food & Drug Administration (USFDA) for Calcitriol softgel capsules in the strengths of 0.25mcg and 0.5mcg, Strides Arcolab said in a statement.

  • Dr Reddy's Launches Generic Anti-viral Tablets in US Market

    Dr Reddy's Launches Generic Anti-viral Tablets in US Market

    The company has launched Valganciclovir tablets, USP in the strength of 450 mg in the US market on December 15, 2014 and the product has been approved by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE today.

  • German Drug Makers Appeal Suspensions Linked to Indian Data

    German Drug Makers Appeal Suspensions Linked to Indian Data

    German drug makers including Stada, Torrent's Heumann and Dr. Reddy's Betapharm have appealed a regulator's decision to suspend approval of some drugs over concerns about clinical trials conducted by an Indian company.

  • Ranbaxy Gets Nod to Launch Anti-Malarial Drug in 7 African Countries

    Ranbaxy Gets Nod to Launch Anti-Malarial Drug in 7 African Countries

    Drug firm Ranbaxy Laboratories has received regulatory nod to launch its indigenously developed anti-malarial drug Synriam in 7 African nations.

  • Scouting For Acquisitions in India: Lupin

    Scouting For Acquisitions in India: Lupin

    The Mumbai-based firm, which is the fifth largest generic player in the US market, has so far stayed away from inorganic growth in India where it clocked revenues of Rs 2,479 crore in the previous fiscal.

  • Bayer Fails to Block Generic Cancer Drug in Supreme Court

    Bayer Fails to Block Generic Cancer Drug in Supreme Court

    German drug maker Bayer has failed in a last-ditch attempt to block the sale of a cheap generic version of its cancer drug Nexavar in India, after the Supreme Court ruled against it on Friday.

  • Prices of 52 More 'Essential' Drugs Capped: Regulator

    Prices of 52 More 'Essential' Drugs Capped: Regulator

    India's drug price authority said in a notice that prices of 52 more drugs, including painkillers and antibiotics, are capped.

  • Lupin Launches Generic Version of Celebrex in US Market

    Lupin Launches Generic Version of Celebrex in US Market

    Its US subsidiary, Lupin Pharmaceuticals Inc has launched the authorised generic for GD Searle LLC's (a subsidiary of Pfizer) Celebrex capsules of strength of 50 mg, 100 mg, 200 mg and 400 mg, the company said in a statement today.

  • Cipla's Arm Meditab Sells Stake in Jiangsu for $18.5 Million

    Cipla's Arm Meditab Sells Stake in Jiangsu for $18.5 Million

    Drug major Cipla today said its Mauritius subsidiary Meditab Holdings has signed a deal to sell its entire 48.22 per cent stake in China-based Jiangsu Cdymax Pharmaceuticals for $18.5 million (over Rs 114 crore).

  • Germany Bans 80 Generic Drugs for Insufficient Trials by GVK

    Germany Bans 80 Generic Drugs for Insufficient Trials by GVK

    The Federal Institute for Drugs and Medical Devices said yesterday it had ordered drug manufacturers, wholesale dealers, medical stores and other outlets not to sell or use these medicines any longer.

  • Cadila Launches First Cheaper Copy of World's Top-Selling Drug

    Cadila Launches First Cheaper Copy of World's Top-Selling Drug

    Drug maker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its US price.

  • Cadila Recalls 15,144 Bottles of Anti-Hypertension Drug in US

    Cadila Recalls 15,144 Bottles of Anti-Hypertension Drug in US

    Cadila Healthcare is voluntarily recalling 15,144 bottles of its anti-hypertension drug Amlodipine Besylate tablets in the US market, according to the US Food and Drug Administration (FDA).

  • Sun Pharma-Ranbaxy Deal Cleared by Fair Trade Regulator

    Sun Pharma-Ranbaxy Deal Cleared by Fair Trade Regulator

    The Competition Commission of India (CCI) on Monday said it has approved generic drug maker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

  • AstraZeneca, Ranbaxy Prevail in Nexium Antitrust Trial

    AstraZeneca, Ranbaxy Prevail in Nexium Antitrust Trial

    The verdict, handed down Friday in federal court in Boston, is the first time a jury has decided such a case since the US Supreme Court ruled last year that so-called "pay-for-delay" settlements may run afoul of antitrust laws.

  • Aurobindo Pharma Completes $132.5 Million Natrol Acquisition

    Aurobindo Pharma Completes $132.5 Million Natrol Acquisition

    Aurobindo Pharma acquired "manufacturing assets, personnel, commercial infrastructure including the nutraceuticals brands in USA of Natrol along with an agreement to take on certain liabilities, with a bid of $132.5 million", the company said in a statement.

  • Ranbaxy Says Europe Bars Imports From Antibiotic Injectables Unit

    Ranbaxy Says Europe Bars Imports From Antibiotic Injectables Unit

    European authorities inspected all units at Ranbaxy's Dewas plant, in Madhya Pradesh, in June and did not approve the manufacturing practices at the unit that makes injectable cephalosporin antibiotics, Ranbaxy said in a stock market filing on Thursday.

  • After US, Germany Bans Export of Ranbaxy's Dewas Plant Drugs

    After US, Germany Bans Export of Ranbaxy's Dewas Plant Drugs

    In fresh overseas troubles, drug maker Ranbaxy has been barred from exporting certain antibiotics produced at its Dewas plant to Germany for non-compliance to 'good manufacturing practice' norms.

Social Sharing

Advertisement

Advertisement

Portfolio

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2014. All rights reserved.